AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Alimera SciencesPharmaxisInnovate BiopharmaceuticalsNeurotropeAcer Therapeutics
SymbolNASDAQ:ALIMOTCMKTS:PXSLYNASDAQ:INNTNASDAQ:NTRPNASDAQ:ACER
Price Information
Current Price$5.26$0.83$0.56$1.39$3.07
52 Week RangeBuyN/ABuyHoldHold
Beat the Market™ Rank
Overall Score1.30.60.60.71.3
Analysis Score3.50.00.01.03.2
Community Score2.52.92.42.32.7
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.60.00.60.00.6
Analyst Ratings
Consensus RecommendationBuyN/ABuyHoldHold
Consensus Price Target$14.50N/A$10.00$1.00$22.33
% Upside from Price Target175.67% upsideN/A1,685.71% upside-28.06% downside627.47% upside
Trade Information
Market Cap$26.06 million$21.86 million$23.72 million$30.79 million$33.52 million
Beta2.250.99-0.392.271.79
Average Volume33,4332,205525,982871,542131,739
Sales & Book Value
Annual Revenue$53.94 million$39.41 millionN/AN/AN/A
Price / Sales0.490.55N/AN/AN/A
CashflowN/A$0.23 per shareN/AN/AN/A
Price / CashN/A3.54N/AN/AN/A
Book Value($7.10) per share$0.40 per share($0.27) per share$1.33 per share$1.37 per share
Price / Book-0.742.08N/AN/AN/A
Profitability
Net Income$-10,440,000.00$4.97 million$-27,050,000.00$-15,140,000.00$-29,420,000.00
EPS($2.19)N/AN/AN/A($2.91)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-15.97%N/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/A-74.56%-127.41%
Return on Assets (ROA)-18.09%N/A-234.42%-71.76%-110.05%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio3.52%N/A0.35%37.32%4.29%
Quick Ratio3.39%N/A0.35%37.32%4.29%
Ownership Information
Institutional Ownership Percentage23.21%N/A5.88%9.68%22.45%
Insider Ownership Percentage14.60%N/A7.90%9.70%20.10%
Miscellaneous
Employees124N/A8623
Shares Outstanding5.03 million26.33 million41.33 million20.95 million10.25 million
Next Earnings Date8/3/2020 (Estimated)N/AN/A6/4/2020 (Estimated)8/11/2020 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.